Paper Details

  1. Home
  2. Paper Details

Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease.

Author: CastiglioneF, CozzolinoA, Di GirolamoE, GrassiaR, MangusoF, MazzaccaG, RispoA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Small bowel bacterial overgrowth is common in Crohn's disease and can be treated effectively with metronidazole or ciprofloxacin. Both antibiotics resulted in improvement of intestinal symptoms, including bloating, stool softness, and abdominal pain.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Small bowel bacterial overgrowth is common in Crohn's disease but its treatment is not clearly defined. Metronidazole and ciprofloxacin are effective antibiotics in active Crohn's disease. AIM: To investigate the efficacy of metronidazole and ciprofloxacin in the treatment of bacterial ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2003.01800.x

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Crohn's Disease

Crohn's disease, a chronic inflammatory bowel disease, can be a challenging condition, often characterized by unpredictable symptoms and complex treatment options. This study delves into the treatment of small bowel bacterial overgrowth (SIBO) in patients with Crohn's disease, exploring a specific aspect of this complex illness. This is like searching for a reliable source of water in the desert of Crohn's disease, seeking to alleviate specific symptoms and improve overall well-being.

The study found that metronidazole and ciprofloxacin were effective in treating SIBO in patients with Crohn's disease, leading to an improvement in intestinal symptoms such as bloating, stool softness, and abdominal pain. This finding suggests that targeting SIBO could be a valuable strategy for managing Crohn's disease and improving patient outcomes. This discovery is like finding a hidden oasis in the desert of Crohn's disease, offering potential relief and symptom management for patients suffering from this debilitating condition.

A Oasis of Relief for Crohn's Patients

The study results highlight the potential of treating SIBO as a means to improve symptoms and overall quality of life for patients with Crohn's disease. This discovery is like finding a hidden oasis in the desert, offering a potential source of relief and a path toward improved well-being. This approach could lead to more effective symptom management and a more manageable experience for those living with Crohn's disease.

A New Approach to Managing Crohn's Disease

This study underscores the importance of considering SIBO as a potential contributing factor to the symptoms of Crohn's disease. Targeting SIBO with antibiotics could be a valuable tool for managing Crohn's disease and improving patient outcomes. This is like discovering a new and effective route through the desert of Crohn's disease, offering a potential path to improved health and well-being.

Dr. Camel's Conclusion

This study sheds light on the potential of treating SIBO in patients with Crohn's disease, offering a potential means to improve symptoms and overall well-being. This discovery is like finding a hidden oasis in the desert of Crohn's disease, offering hope for a more manageable and fulfilling life for those living with this challenging condition.

Date :
  1. Date Completed 2004-02-02
  2. Date Revised 2019-09-01
Further Info :

Pubmed ID

14653830

DOI: Digital Object Identifier

10.1046/j.1365-2036.2003.01800.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.